Complex sense-antisense architecture of TNFAIP1/POLDIP2 on 17q11.2 represents a novel transcriptional structural-functional gene module involved in breast cancer progression

BMC Genomics

Volumn 11, Issue SUPPL. 1, 2010, Pages

  Grinchuk, Oleg V ^a   Motakis, Efthimios ^a   Kuznetsov, Vladimir A ^a  

^a BIOINFORMATICS INSTITUTE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLINE; MEMBRANE PROTEIN; ONCOPROTEIN; PROTEIN IFT20; PROTEIN POLDIP2; PROTEIN TMEM199; PROTEIN TMEM97; PROTEIN TNFAIP I; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; COMPLEMENTARY DNA; NUCLEAR PROTEIN; POLDIP2 PROTEIN, HUMAN; PROTEIN; TNFAIP1 PROTEIN, HUMAN;

ARCHITECTURE; ARTICLE; BREAST CANCER; CANCER GROWTH; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMOSOME 17Q; CONTROLLED STUDY; FUNCTIONAL GENOMICS; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GENE LOCUS; GENE OVEREXPRESSION; GENE STRUCTURE; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PROTEIN DOMAIN; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; BREAST TUMOR; CHROMOSOME 17; CODON; DISEASE COURSE; GENE DOSAGE; GENE EXPRESSION REGULATION; GENETICS; PATHOLOGY; SURVIVAL RATE; TUMOR CELL LINE;

EUKARYOTA;

BREAST NEOPLASMS; CELL LINE, TUMOR; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMOSOMES, HUMAN, PAIR 17; CODON; DISEASE PROGRESSION; DNA, ANTISENSE; GENE DOSAGE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; NUCLEAR PROTEINS; PROTEINS; SURVIVAL RATE; TRANSCRIPTION, GENETIC;

EID: 76749129707     PISSN: None     EISSN: 14712164     Source Type: Journal    
DOI: 10.1186/1471-2164-11-S1-S9     Document Type: Article

References (62)

1. Yu W, Gius D, Onyango P, Muldoon-Jacobs K, Karp J, Feinberg AP, Cui H. Epigenetic silencing of tumour suppressor gene p15 by its antisense RNA. Nature 2008, 451(7175):202-206. 10.1038/nature06468, 2743558, 18185590.
2. Orfanelli U, Wenke AK, Doglioni C, Russo V, Bosserhoff AK, Lavorgna G. Identification of novel sense and antisense transcription at the TRPM2 locus in cancer. Cell research 2008, 18(11):1128-1140. 10.1038/cr.2008.296, 18957938.
3. Guo JH, Cheng HP, Yu L, Zhao S. Natural antisense transcripts of Alzheimer's disease associated genes. DNA Seq 2006, 17(2):170-173. 10.1080/10425170600609165, 17076261.
4. Juszczynski P, Kutok JL, Li C, Mitra J, Aguiar RC, Shipp MA. BAL1 and BBAP are regulated by a gamma interferon-responsive bidirectional promoter and are overexpressed in diffuse large B-cell lymphomas with a prominent inflammatory infiltrate. Molecular and cellular biology 2006, 26(14):5348-5359. 10.1128/MCB.02351-05, 1592708, 16809771.
5. Kuznetsov VA, George J, Orlov Y. Genome-wide co-expression patterns of human cis-antisense gene pairs. The 5-th Intern Conf on Bioinformatics of Genome regulation and structures: 2006 2006, 90-93. Novosibirsk, Institute of Cytology&Genetics, Russia.
6. Makalowska I. Comparative analysis of an unusual gene arrangement in the human chromosome 1. Gene 2008, 423(2):172-179. 10.1016/j.gene.2008.06.030, 18672041.
7. Ohinata Y, Sutou S, Kondo M, Takahashi T, Mitsui Y. Male-enhanced antigen-1 gene flanked by two overlapping genes is expressed in late spermatogenesis. Biology of reproduction 2002, 67(6):1824-1831. 10.1095/biolreprod.101.002550, 12444059.
8. Veeramachaneni V, Makalowski W, Galdzicki M, Sood R, Makalowska I. Mammalian overlapping genes: the comparative perspective. Genome research 2004, 14(2):280-286. 10.1101/gr.1590904, 327103, 14762064.
9. Engstrom PG, Suzuki H, Ninomiya N, Akalin A, Sessa L, Lavorgna G, Brozzi A, Luzi L, Tan SL, Yang L, et al. Complex Loci in human and mouse genomes. PLoS genetics 2006, 2(4):e47. 10.1371/journal.pgen.0020047, 1449890, 16683030.
10. Makalowska I, Lin CF, Makalowski W. Overlapping genes in vertebrate genomes. Computational biology and chemistry 2005, 29(1):1-12. 10.1016/j.compbiolchem.2004.12.006, 15680581.
11. Hinnis AR, Luckett JC, Walker RA. Survivin is an independent predictor of short-term survival in poor prognostic breast cancer patients. British journal of cancer 2007, 96(4):639-645. 10.1038/sj.bjc.6603616, 2360044, 17285125.
12. Hu X, Stern HM, Ge L, O'Brien C, Haydu L, Honchell CD, Haverty PM, Peters BA, Wu TD, Amler LC, et al. Genetic alterations and oncogenic pathways associated with breast cancer subtypes. Mol Cancer Res 2009, 7(4):511-522. 10.1158/1541-7786.MCR-08-0107, 19372580.
13. Haverty PM, Hon LS, Kaminker JS, Chant J, Zhang Z. High-resolution analysis of copy number alterations and associated expression changes in ovarian tumors. BMC medical genomics 2009, 2:21. 10.1186/1755-8794-2-21, 2694826, 19419571.
14. Bempt I, Drijkoningen M, De Wolf-Peeters C. The complexity of genotypic alterations underlying HER2-positive breast cancer: an explanation for its clinical heterogeneity. Current opinion in oncology 2007, 19(6):552-557. 10.1097/CCO.0b013e3282f0ad8e, 17906451.
15. Rody A, Karn T, Ruckhaberle E, Muller V, Gehrmann M, Solbach C, Ahr A, Gatje R, Holtrich U, Kaufmann M. Gene expression of topoisomerase II alpha (TOP2A) by microarray analysis is highly prognostic in estrogen receptor (ER) positive breast cancer. Breast cancer research and treatment 2009, 113(3):457-466. 10.1007/s10549-008-9964-x, 18340528.
16. Ivshina AV, George J, Senko O, Mow B, Putti TC, Smeds J, Lindahl T, Pawitan Y, Hall P, Nordgren H, et al. Genetic reclassification of histologic grade delineates new clinical subtypes of breast cancer. Cancer research 2006, 66(21):10292-10301. 10.1158/0008-5472.CAN-05-4414, 17079448.
17. Barlett M. Test of significance in factor analysis. BrJPsychol 1950, 3:77-85.
18. Efron B, Tibshirani RJ. An Introduction to the bootstrap. 1994, New York: Chapman and Hall.
19. Box GEP. A general distribution theory for a class of likelihood criteria. Biometrika 1949, 36(3-4):317-346. 10.1093/biomet/36.3-4.317, 15402070.
20. Motakis E, Ivshina AV, Kuznetsov VA. Data-driven approach to predict survival of cancer patients: estimation of microarray genes' prediction significance by Cox proportional hazard regression model. IEEE Eng Med Biol Mag 2009, 28(4):58-66. 10.1109/MEMB.2009.932937, 19622426.
21. Cox R, Oakes D. Analysis of survival data. 1984, London: Chapman and Hill.
22. Orlov YL, Zhou J, Lipovich L, Shahab A, Kuznetsov VA. Quality assessment of the Affymetrix U133A&B probesets by target sequence mapping and expression data analysis. In silico biology 2007, 7(3):241-260.
23. Liu L, Rodriguez-Belmonte EM, Mazloum N, Xie B, Lee MY. Identification of a novel protein, PDIP38, that interacts with the p50 subunit of DNA polymerase delta and proliferating cell nuclear antigen. The Journal of biological chemistry 2003, 278(12):10041-10047. 10.1074/jbc.M208694200, 12522211.
24. Wolf FW, Marks RM, Sarma V, Byers MG, Katz RW, Shows TB, Dixit VM. Characterization of a novel tumor necrosis factor-alpha-induced endothelial primary response gene. The Journal of biological chemistry 1992, 267(2):1317-1326.
25. Zhou J, Hu X, Xiong X, Liu X, Liu Y, Ren K, Jiang T, Hu X, Zhang J. Cloning of two rat PDIP1 related genes and their interactions with proliferating cell nuclear antigen. Journal of experimental zoology 2005, 303(3):227-240.
26. Saldanha AJ. Java Treeview--extensible visualization of microarray data. Bioinformatics (Oxford, England) 2004, 20(17):3246-3248. 10.1093/bioinformatics/bth349, 15180930.
27. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society Series B (Methodological) 1995, 57:289-300.
28. Benjamini Y, Yekutieli D. The control of the false discovery rate in multiple testing under dependency. Annals of statistics 2001, 29:1165-1188.
29. Moparthi SB, Arbman G, Wallin A, Kayed H, Kleeff J, Zentgraf H, Sun XF. Expression of MAC30 protein is related to survival and biological variables in primary and metastatic colorectal cancers. International journal of oncology 2007, 30(1):91-95.
30. Arriola E, Marchio C, Tan DS, Drury SC, Lambros MB, Natrajan R, Rodriguez-Pinilla SM, Mackay A, Tamber N, Fenwick K, et al. Genomic analysis of the HER2/TOP2A amplicon in breast cancer and breast cancer cell lines. Laboratory investigation; a journal of technical methods and pathology 2008, 88(5):491-503. 10.1038/labinvest.2008.19, 18332872.
31. Bieche I, Tomasetto C, Regnier CH, Moog-Lutz C, Rio MC, Lidereau R. Two distinct amplified regions at 17q11-q21 involved in human primary breast cancer. Cancer research 1996, 56(17):3886-3890.
32. Kauraniemi P, Kuukasjarvi T, Sauter G, Kallioniemi A. Amplification of a 280-kilobase core region at the ERBB2 locus leads to activation of two hypothetical proteins in breast cancer. The American journal of pathology 2003, 163(5):1979-1984. 1892409, 14578197.
33. Kauraniemi P, Kallioniemi A. Activation of multiple cancer-associated genes at the ERBB2 amplicon in breast cancer. Endocrine-related cancer 2006, 13(1):39-49. 10.1677/erc.1.01147, 16601278.
34. Kao J, Pollack JR. RNA interference-based functional dissection of the 17q12 amplicon in breast cancer reveals contribution of coamplified genes. Genes, chromosomes & cancer 2006, 45(8):761-769. 10.1002/gcc.20339, 16708353.
35. Ethier SP. Identifying and validating causal genetic alterations in human breast cancer. Breast cancer research and treatment 2003, 78(3):285-287. 10.1023/A:1023078722316, 12755487.
36. Chin SF, Wang Y, Thorne NP, Teschendorff AE, Pinder SE, Vias M, Naderi A, Roberts I, Barbosa-Morais NL, Garcia MJ, et al. Using array-comparative genomic hybridization to define molecular portraits of primary breast cancers. Oncogene 2007, 26(13):1959-1970. 10.1038/sj.onc.1209985, 17001317.
37. Cohen BA, Mitra RD, Hughes JD, Church GM. A computational analysis of whole-genome expression data reveals chromosomal domains of gene expression. Nature genetics 2000, 26(2):183-186. 10.1038/79896, 11017073.
38. Spellman PT, Rubin GM. Evidence for large domains of similarly expressed genes in the Drosophila genome. Journal of biology 2002, 1(1):5. 10.1186/1475-4924-1-5, 117248, 12144710.
39. Reyal F, Stransky N, Bernard-Pierrot I, Vincent-Salomon A, de Rycke Y, Elvin P, Cassidy A, Graham A, Spraggon C, Desille Y, et al. Visualizing chromosomes as transcriptome correlation maps: evidence of chromosomal domains containing co-expressed genes--a study of 130 invasive ductal breast carcinomas. Cancer research 2005, 65(4):1376-1383. 10.1158/0008-5472.CAN-04-2706, 15735024.
40. Barski A, Cuddapah S, Cui K, Roh TY, Schones DE, Wang Z, Wei G, Chepelev I, Zhao K. High-resolution profiling of histone methylations in the human genome. Cell 2007, 129(4):823-837. 10.1016/j.cell.2007.05.009, 17512414.
41. Zhao XD, Han X, Chew JL, Liu J, Chiu KP, Choo A, Orlov YL, Sung WK, Shahab A, Kuznetsov VA, et al. Whole-genome mapping of histone H3 Lys4 and 27 trimethylations reveals distinct genomic compartments in human embryonic stem cells. Cell stem cell 2007, 1(3):286-298. 10.1016/j.stem.2007.08.004, 18371363.
42. Robertson G, Hirst M, Bainbridge M, Bilenky M, Zhao Y, Zeng T, Euskirchen G, Bernier B, Varhol R, Delaney A, et al. Genome-wide profiles of STAT1 DNA association using chromatin immunoprecipitation and massively parallel sequencing. Nature methods 2007, 4(8):651-657. 10.1038/nmeth1068, 17558387.
43. Liu M, Sun Z, Zhou A, Li H, Yang L, Zhou C, Liu R, Hu X, Zhou J, Xiang S, et al. Functional characterization of the promoter region of human TNFAIP1 gene. Molecular biology reports 2009,
44. Welboren WJ, van Driel MA, Janssen-Megens EM, van Heeringen SJ, Sweep FC, Span PN, Stunnenberg HG. ChIP-Seq of ERalpha and RNA polymerase II defines genes differentially responding to ligands. The EMBO journal 2009, 28(10):1418-1428. 10.1038/emboj.2009.88, 19339991.
45. Yelin R, Dahary D, Sorek R, Levanon EY, Goldstein O, Shoshan A, Diber A, Biton S, Tamir Y, Khosravi R, et al. Widespread occurrence of antisense transcription in the human genome. Nature biotechnology 2003, 21(4):379-386. 10.1038/nbt808, 12640466.
46. Katayama S, Tomaru Y, Kasukawa T, Waki K, Nakanishi M, Nakamura M, Nishida H, Yap CC, Suzuki M, Kawai J, et al. Antisense transcription in the mammalian transcriptome. Science (New York, NY) 2005, 309(5740):1564-1566.
47. Baguma-Nibasheka M, Li AW, Osman MS, Geldenhuys L, Casson AG, Too CK, Murphy PR. Coexpression and regulation of the FGF-2 and FGF antisense genes in leukemic cells. Leukemia research 2005, 29(4):423-433. 10.1016/j.leukres.2004.09.006, 15725477.
48. Paunesku T, Mittal S, Protic M, Oryhon J, Korolev SV, Joachimiak A, Woloschak GE. Proliferating cell nuclear antigen (PCNA). International journal of radiation biology 2001, 77(10):1007-1021. 10.1080/09553000110069335, 11682006.
49. Aaltomaa S, Lipponen P, Syrjanen K. Proliferating cell nuclear antigen (PCNA) immunolabeling as a prognostic factor in axillary lymph node negative breast cancer. Anticancer research 1993, 13(2):533-538.
50. Sledge GW, Miller KD. Exploiting the hallmarks of cancer: the future conquest of breast cancer. Eur J Cancer 2003, 39(12):1668-1675. 10.1016/S0959-8049(03)00273-9, 12888360.
51. Malkas LH, Herbert BS, Abdel-Aziz W, Dobrolecki LE, Liu Y, Agarwal B, Hoelz D, Badve S, Schnaper L, Arnold RJ, et al. A cancer-associated PCNA expressed in breast cancer has implications as a potential biomarker. Proceedings of the National Academy of Sciences of the United States of America 2006, 103(51):19472-19477. 10.1073/pnas.0604614103, 1697829, 17159154.
52. Zhou J, Ren K, Liu X, Xiong X, Hu X, Zhang J. A novel PDIP1-related protein, KCTD10, that interacts with proliferating cell nuclear antigen and DNA polymerase delta. Biochimica et biophysica acta 2005, 1729(3):200-203.
53. Wang Y, Zheng Y, Luo F, Fan X, Chen J, Zhang C, Hui R. KCTD10 interacts with proliferating cell nuclear antigen and its down-regulation could inhibit cell proliferation. Journal of cellular biochemistry 2009, 106(3):409-413. 10.1002/jcb.22026, 19125419.
54. Yang L, Liu N, Hu X, Zhang W, Wang T, Li H, Zhang B, Xiang S, Zhou J, Zhang J. CK2 phosphorylates TNFAIP1 to affect its subcellular localization and interaction with PCNA. Molecular biology reports 2009,
55. Kim DM, Chung KS, Choi SJ, Jung YJ, Park SK, Han GH, Ha JS, Song KB, Choi NS, Kim HM, et al. RhoB induces apoptosis via direct interaction with TNFAIP1 in HeLa cells. International journal of cancer 2009, 125(11):2520-2527.
56. Scully R, Chen J, Ochs RL, Keegan K, Hoekstra M, Feunteun J, Livingston DM. Dynamic changes of BRCA1 subnuclear location and phosphorylation state are initiated by DNA damage. Cell 1997, 90(3):425-435. 10.1016/S0092-8674(00)80503-6, 9267023.
57. Svetlova MP, Solovjeva LV, Nikiforov AA, Chagin VA, Lehmann AR, Tomilin NV. Staurosporine-sensitive protein phosphorylation is required for postreplication DNA repair in human cells. FEBS letters 1998, 428(1-2):23-26. 10.1016/S0014-5793(98)00477-3, 9645467.
58. Klaile E, Kukalev A, Obrink B, Muller MM. PDIP38 is a novel mitotic spindle-associated protein that affects spindle organization and chromosome segregation. Cell cycle (Georgetown, Tex) 2008, 7(20):3180-3186.
59. Jonassen JA, San Agustin J, Follit JA, Pazour GJ. Deletion of IFT20 in the mouse kidney causes misorientation of the mitotic spindle and cystic kidney disease. The Journal of cell biology 2008, 183(3):377-384. 10.1083/jcb.200808137, 2575779, 18981227.
60. Klaile E, Muller MM, Kannicht C, Otto W, Singer BB, Reutter W, Obrink B, Lucka L. The cell adhesion receptor carcinoembryonic antigen-related cell adhesion molecule 1 regulates nucleocytoplasmic trafficking of DNA polymerase delta-interacting protein 38. The Journal of biological chemistry 2007, 282(36):26629-26640. 10.1074/jbc.M701807200, 17623671.
61. Cheng X, Kanki T, Fukuoh A, Ohgaki K, Takeya R, Aoki Y, Hamasaki N, Kang D. PDIP38 associates with proteins constituting the mitochondrial DNA nucleoid. Journal of biochemistry 2005, 138(6):673-678. 10.1093/jb/mvi169, 16428295.
62. Wahlestedt C. Natural antisense and noncoding RNA transcripts as potential drug targets. Drug discovery today 2006, 11(11-12):503-508. 10.1016/j.drudis.2006.04.013, 16713901.